AstraZeneca and Incyte to conduct new lung cancer clinical trial

AstraZeneca is expanding its partnership with Incyte to launch a new lung cancer clinical trial collaboration.

The new collaboration will evaluate the efficacy and safety of Incyte's Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca's next generation epidermal growth factor receptor (EGFR) inhibitor Tagrisso.

Together, the therapies will be assessed as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer who have been treated with a first-generation EGFR tyrosine kinase inhibitor and subsequently developed the T790M resistance mutation.

A phase I/II study will be conducted by Incyte, with the phase I part of the trial expected to establish a recommended dose regimen, while the phase II portion will assess the therapy's safety and efficacy profile.

Antoine Yver, head of oncology for global medicines development at AstraZeneca, said: "We are pleased to be building on our existing relationship with Incyte and exploring a potentially exciting combination for lung cancer patients who have developed a resistance to first-generation EGFR inhibitor treatment."

The company also recently announced that it will be carrying out secretome-oriented research as part of a new study collaboration with the Wallenberg Centre for Protein Research.